Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has been given a $85.00 price target by Oppenheimer Holdings, Inc. in a research report issued on Tuesday. The brokerage presently has a “buy” rating on the stock. Oppenheimer Holdings, Inc.’s price target indicates a potential upside of 17.99% from the stock’s previous close.
Several other research analysts also recently weighed in on NBIX. BMO Capital Markets lifted their target price on shares of Neurocrine Biosciences from $75.00 to $84.00 and gave the stock an “outperform” rating in a research report on Friday, August 4th. Cowen and Company reissued an “outperform” rating and issued a $65.00 target price (up from $60.00) on shares of Neurocrine Biosciences in a research report on Wednesday, August 9th. BidaskClub raised shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research report on Wednesday, August 9th. Piper Jaffray Companies set a $68.00 target price on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a research report on Thursday, August 24th. Finally, ValuEngine raised shares of Neurocrine Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. One investment analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $78.88.
Neurocrine Biosciences (NASDAQ NBIX) traded down $2.13 during trading on Tuesday, hitting $72.04. 916,600 shares of the stock traded hands, compared to its average volume of 1,126,160. The company has a current ratio of 14.38, a quick ratio of 14.37 and a debt-to-equity ratio of 1.05. Neurocrine Biosciences has a 1-year low of $37.35 and a 1-year high of $75.98.
Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Wednesday, November 1st. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.36. The firm had revenue of $60.77 million during the quarter, compared to analysts’ expectations of $29.38 million. During the same period last year, the business earned ($0.43) earnings per share. equities research analysts predict that Neurocrine Biosciences will post -1.74 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece was originally posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.truebluetribune.com/2017/11/16/neurocrine-biosciences-inc-nbix-given-a-85-00-price-target-by-oppenheimer-holdings-inc-analysts.html.
In other news, insider Kyle Gano sold 24,818 shares of the business’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $71.05, for a total value of $1,763,318.90. Following the completion of the sale, the insider now directly owns 84,596 shares in the company, valued at $6,010,545.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Dimitri E. Grigoriadis sold 30,000 shares of the business’s stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $74.58, for a total transaction of $2,237,400.00. Following the completion of the sale, the insider now owns 77,691 shares of the company’s stock, valued at $5,794,194.78. The disclosure for this sale can be found here. Insiders sold 140,810 shares of company stock valued at $9,035,398 over the last quarter. Corporate insiders own 4.80% of the company’s stock.
Institutional investors have recently modified their holdings of the company. First Trust Advisors LP lifted its stake in shares of Neurocrine Biosciences by 29.0% in the third quarter. First Trust Advisors LP now owns 782,685 shares of the company’s stock worth $47,963,000 after buying an additional 176,136 shares during the last quarter. Canada Pension Plan Investment Board lifted its stake in shares of Neurocrine Biosciences by 49.7% in the second quarter. Canada Pension Plan Investment Board now owns 24,700 shares of the company’s stock worth $1,136,000 after buying an additional 8,200 shares during the last quarter. Artisan Partners Limited Partnership acquired a new stake in shares of Neurocrine Biosciences in the second quarter worth $15,981,000. Davidson Kempner Capital Management LP acquired a new stake in shares of Neurocrine Biosciences in the second quarter worth $3,639,000. Finally, California Public Employees Retirement System lifted its stake in shares of Neurocrine Biosciences by 2.2% in the second quarter. California Public Employees Retirement System now owns 179,300 shares of the company’s stock worth $8,248,000 after buying an additional 3,900 shares during the last quarter.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.